S&P 500 Top Gainer and Loser - Alexion Pharm. (ALXN) Gets BIG Push

TL;DR

Alexion Pharmaceuticals is being bought out by AstraZeneca for $39 billion, offering potential investment opportunities. Occidental Petroleum experienced a significant decrease in stock value but will not be further analyzed in this video.

Transcript

hey guys it's december 14th uh the market's closing here in a minute so pretty much the uh the day is over we have two stocks to look at today reminder we're always going to be doing the biggest gainer and the biggest loser in the s p by percentage every day now for the biggest gainer we have a company called alexion pharmaceuticals they were just ... Read More

Key Insights

• ❓ AstraZeneca's acquisition of Alexion Pharmaceuticals highlights the potential growth and value in the pharmaceutical industry.
• 😷 Alexion Pharmaceuticals' expertise in developing drugs for rare medical conditions gives them a unique advantage in the market.
• ✋ The financials of Alexion Pharmaceuticals, including revenue and profit growth, are impressive, but the high valuation may pose a risk for potential investors.
• 🎮 Occidental Petroleum experienced a significant decrease in stock value and will not be further analyzed in this video.

Questions & Answers

Q: Why is AstraZeneca acquiring Alexion Pharmaceuticals?

AstraZeneca is acquiring Alexion Pharmaceuticals for $39 billion to expand its portfolio and gain access to their expertise in developing drugs for rare medical conditions.

Q: What makes Alexion Pharmaceuticals' blockbuster product, Solaris, unique?

Solaris is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and targets rare diseases with high unmet medical needs in various fields such as hematology, nephrology, and neurology.

Q: Why did Alexion Pharmaceuticals experience a significant increase in profits?

Alexion Pharmaceuticals had a massive jump in profit from $78 million to $2.4 billion. This increase can be attributed to factors such as a one-time gain or a significant event that boosted their revenue. Further research is needed to determine the exact reason.

Q: Should investors consider buying Alexion Pharmaceuticals' stock?

The financials of Alexion Pharmaceuticals look promising, with significant revenue and profit growth. However, the current valuation at 43 times free cash flow may be a concern. Investors should closely monitor the situation, especially if the AstraZeneca deal falls through.

Summary & Key Takeaways

• Alexion Pharmaceuticals is being acquired by AstraZeneca for $39 billion, which is higher than its current market cap of $34 billion.

• Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions.

• The company has shown significant revenue and profit growth in recent years.